Investment analysts at StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Rating) in a research note issued on Monday. The firm set a “sell” rating on the medical equipment provider’s stock.
Aethlon Medical Trading Up 1.8 %
NASDAQ:AEMD opened at $0.32 on Monday. The stock has a fifty day moving average price of $0.37 and a 200 day moving average price of $0.41. Aethlon Medical has a 12-month low of $0.23 and a 12-month high of $2.46. The firm has a market cap of $7.24 million, a PE ratio of -0.43 and a beta of 1.18.
Institutional Investors Weigh In On Aethlon Medical
Several institutional investors have recently modified their holdings of the company. Buckingham Strategic Partners purchased a new stake in Aethlon Medical during the 3rd quarter worth about $29,000. Vanguard Group Inc. raised its position in shares of Aethlon Medical by 112.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,053,198 shares of the medical equipment provider’s stock worth $613,000 after acquiring an additional 558,596 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Aethlon Medical by 11.6% during the first quarter. Renaissance Technologies LLC now owns 270,297 shares of the medical equipment provider’s stock worth $395,000 after purchasing an additional 28,097 shares during the last quarter. Citadel Advisors LLC acquired a new position in Aethlon Medical in the third quarter valued at approximately $72,000. Finally, Two Sigma Investments LP increased its stake in Aethlon Medical by 219.3% in the first quarter. Two Sigma Investments LP now owns 127,341 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 87,458 shares during the last quarter. 11.86% of the stock is owned by hedge funds and other institutional investors.
About Aethlon Medical
Aethlon Medical, Inc is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI.
Featured Articles
- Get a free copy of the StockNews.com research report on Aethlon Medical (AEMD)
- MarketBeat Week in Review – 5/29 – 6/2
- Trading Channel Breakout in Lululemon Brought by Earnings
- What Should Investors Make of These 3 Dividend Cuts?
- Constellation Brands Taps into Growth: Analysts Bullish on Stock
- CrowdStrike: Another Tech Stock to Buy on the Dip
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
